Skip to main content

Articles

Page 12 of 17

  1. Two phase 3 trials compared 28–35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous ...

    Authors: Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher, Andreas Clemens, Stefan Hantel, Martin Feuring, Jörg Kreuzer, Michael Huo and Richard J. Friedman
    Citation: Thrombosis Journal 2015 13:36
    Content type: Original clinical investigation Published on:

  2. Venous thromboembolism (VTE) could be manifested as deep venous thrombosis (DVT) or pulmonary embolism (PE). DVT is usually the more common manifestation and is usually formation of a thrombus in the deep vein...

    Authors: Soudabeh Hosseini, Ebrahim Kalantar, Maryam Sadat Hosseini, Shadi Tabibian, Morteza Shamsizadeh and Akbar Dorgalaleh
    Citation: Thrombosis Journal 2015 13:35
    Content type: Original basic research Published on:

  3. Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influenc...

    Authors: Giancarlo Agnelli, Anselm K. Gitt, Rupert Bauersachs, Eva-Maria Fronk, Petra Laeis, Patrick Mismetti, Manuel Monreal, Stefan N. Willich, Wolf-Peter Wolf and Alexander T. Cohen
    Citation: Thrombosis Journal 2015 13:41
    Content type: Original clinical investigation Published on:

  4. The aim was to assess the risk of venous thromboembolism (VTE) associated with use of combined oral contraceptives (COCs) in women with a family history of VTE.

    Authors: Bengt Zöller, Henrik Ohlsson, Jan Sundquist and Kristina Sundquist
    Citation: Thrombosis Journal 2015 13:34
    Content type: Original clinical investigation Published on:

  5. Deep vein thrombosis (DVT) and pulmonary emboli (PE), known together as venous thromboembolic (VTE) disease remain major complications following elective hip and knee surgery. This study compares three chemopr...

    Authors: Murray M. Bern, Diane Hazel, Elizabeth Deeran, John R. Richmond, Daniel M. Ward, Damon J. Spitz, David A. Mattingly, James V. Bono, Ronna H. Berezin, Laura Hou, Gerald B. Miley and Benjamin E. Bierbaum
    Citation: Thrombosis Journal 2015 13:32
    Content type: Original clinical investigation Published on:

  7. Platelet activation, thrombin generation and fibrin formation play important roles in intracoronary thrombus formation, which may lead to acute myocardial infarction.

    Authors: C. H. Hansen, V. Ritschel, S. Halvorsen, G. Ø. Andersen, R. Bjørnerheim, J. Eritsland, H. Arnesen and I. Seljeflot
    Citation: Thrombosis Journal 2015 13:31
    Content type: Original clinical investigation Published on:

  8. We report a case of unsuccessful percutaneous mechanical thrombectomy in treatment of a high-risk pulmonary embolism (PE). Pulmonary thromboemboli are commonly expected as a homogenous mass, rich with red bloo...

    Authors: Jernej Vidmar, Igor Serša, Eduard Kralj and Peter Popovič
    Citation: Thrombosis Journal 2015 13:30
    Content type: Case report Published on:

  9. Dual antiplatelet therapy based on the combination of an adenosine diphosphate (ADP)-receptor antagonist plus aspirin has demonstrated to be more effective in reducing the rate of major ischemic vascular event...

    Authors: Hernan Polo Friz, Mauro Molteni and Claudio Cimminiello
    Citation: Thrombosis Journal 2015 13:28
    Content type: Review Published on:

  10. Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy has been the mainstay of antithrombotic treatment for reducing the risk of stroke in AF. However, warfarin ha...

    Authors: Alpesh Amin and Steven Deitelzweig
    Citation: Thrombosis Journal 2015 13:29
    Content type: Review Published on:

  11. In the absence of thromboprophylaxis, patients undergoing total hip arthroplasty (THA) are at increased risk for venous thromboembolism (VTE). The objective of this study was to compare the efficacy and safety...

    Authors: Takeshi Fuji, Satoru Fujita, Yohko Kawai, Mashio Nakamura, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe and Shintaro Tachibana
    Citation: Thrombosis Journal 2015 13:27
    Content type: Original clinical investigation Published on:

  12. Although quantitative anti-FXa assays can be used to measure rivaroxaban plasma levels, they are not widely performed or available. We aimed to tentatively determine the cut-off for thromboembolism and bleedin...

    Authors: Raul Altman and Claudio Daniel Gonzalez
    Citation: Thrombosis Journal 2015 13:26
    Content type: Original clinical investigation Published on:

  13. A 43-year-old woman recipient of a bare metal coronary stent during an acute anterior myocardial infarction was repeatedly hospitalized with recurrent stent thrombosis (ST) over the following 3 years. Emergent...

    Authors: Takao Konishi, Tadashi Yamamoto, Naohiro Funayama, Beni Yamaguchi, Seiichiro Sakurai, Hiroshi Nishihara, Koko Yamazaki, Yusuke Kashiwagi, Yasuki Sasa, Mitsuru Gima, Hideichi Tanaka, Daisuke Hotta and Kenjiro Kikuchi
    Citation: Thrombosis Journal 2015 13:25
    Content type: Case report Published on:

  14. Plasma phospholipid transfer protein (PLTP) transfers lipids between donors and acceptors (e.g., from HDL to VLDL) and modulates lipoprotein composition, size, and levels. No study has reported an assessment of t...

    Authors: Hiroshi Deguchi, Gertrud Wolfbauer, Marian C. Cheung, Yajnavalka Banerjee, Darlene J. Elias, José A. Fernández, John J. Albers and John H. Griffin
    Citation: Thrombosis Journal 2015 13:24
    Content type: Original basic research Published on:

  16. The introduction of central venous catheters has advanced medical care, particularly in hemato-oncology. However these can be associated with an increased thrombotic risk. Previous studies have compared the ra...

    Authors: Priya Sriskandarajah, Katharine Webb, David Chisholm, Ravi Raobaikady, Kim Davis, Natalie Pepper, Mark E Ethell, Mike N Potter and Bronwen E Shaw
    Citation: Thrombosis Journal 2015 13:21
    Content type: Original clinical investigation Published on:

  17. Venous thromboembolism (VTE) is a burden on healthcare systems. Standard treatment involves parenteral anticoagulation overlapping with a vitamin K antagonist, an approach that is effective but associated with...

    Authors: Luke Bamber, Dominic Muston, Euan McLeod, Anne Guillermin, Julia Lowin and Raj Patel
    Citation: Thrombosis Journal 2015 13:20
    Content type: Original basic research Published on:

  18. The clinical picture of deep vein thrombosis (DVT) is nonspecific. Therefore assessment of the probability of occurrence of DVT plays a very important part in making a correct diagnosis of DVT.

    Authors: Małgorzata Dybowska, Witold Z Tomkowski, Paweł Kuca, Rafał Ubysz, Adam Jóźwik and Dariusz Chmielewski
    Citation: Thrombosis Journal 2015 13:18
    Content type: Original clinical investigation Published on:

  19. Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for the prevention and treatment of venous thromboembolism and for stroke prevention in patients with atrial fibrillation. NOACs do no...

    Authors: Hein Heidbuchel, Dana Berti, Manuel Campos, Lien Desteghe, Ana Parente Freixo, António Robalo Nunes, Vanessa Roldán, Vincenzo Toschi and Riitta Lassila
    Citation: Thrombosis Journal 2015 13:22
    Content type: Review Published on:

  20. Autoinflammatory diseases are a group of disorders due to acquired or hereditary disfunction of innate immune system and characterized by systemic or localized manifestations. The prototype is Familial Mediter...

    Authors: Micaela La Regina, Francesco Orlandini and Raffaele Manna
    Citation: Thrombosis Journal 2015 13:19
    Content type: Review Published on:

  21. The contact system, also named as plasma kallikrein-kinin system, consists of three serine proteinases: coagulation factors XII (FXII) and XI (FXI), and plasma prekallikrein (PK), and the nonenzymatic cofactor...

    Authors: Yi Wu
    Citation: Thrombosis Journal 2015 13:17
    Content type: Review Published on:

  22. Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune disease. Clinical presentation is extremely variable and heterogeneous. It has been shown that SLE itself is an independent risk factor...

    Authors: Mario Bazzan, Antonella Vaccarino and Fabio Marletto
    Citation: Thrombosis Journal 2015 13:16
    Content type: Review Published on:

  23. In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now clear that immune and coagulation systems are functionally interconnected.

    Authors: Giacomo Emmi, Elena Silvestri, Danilo Squatrito, Amedeo Amedei, Elena Niccolai, Mario Milco D’Elios, Chiara Della Bella, Alessia Grassi, Matteo Becatti, Claudia Fiorillo, Lorenzo Emmi, Augusto Vaglio and Domenico Prisco
    Citation: Thrombosis Journal 2015 13:15
    Content type: Review Published on:

  24. Inflammatory bowel disease affects more than 2 million people in Europe, with almost 20% of patients being diagnosed in pediatric age. Patients with inflammatory bowel disease are at increased risk of thromboe...

    Authors: Martina Giannotta, Gherardo Tapete, Giacomo Emmi, Elena Silvestri and Monica Milla
    Citation: Thrombosis Journal 2015 13:14
    Content type: Review Published on:

  25. Deep vein thrombosis (DVT) is a common disease and is associated with pulmonary embolism (PE). Proximal iliofemoral DVT may lead to severe PE and chronic venous insufficiency. The standard therapy for DVT is a...

    Authors: Norimichi Koitabashi, Nogiku Niwamae, Tetsuya Taguchi, Yoshiaki Ohyama, Noriaki Takama and Masahiko Kurabayashi
    Citation: Thrombosis Journal 2015 13:13
    Content type: Case report Published on:

  26. Obesity is currently regarded as a pro-inflammatory condition during which leptin (Ob gene product) might act as a risk factor for Cardiovascular Diseases (CVD) including Acute Myocardial Infarction (AMI). There ...

    Authors: Devarajan Nalini, Rajendran Karthick, Vijay Shirin, Ganesan Manohar and Raghunathan Malathi
    Citation: Thrombosis Journal 2015 13:12
    Content type: Original clinical investigation Published on:

  27. The Editors of Thrombosis Journal would like to thank all of our reviewers who have contributed to the journal in Volume 12 (2014) and whose valuable support is fundamental to its success.

    Authors: Yukio Ozaki and Hugo ten Cate
    Citation: Thrombosis Journal 2015 13:11
    Content type: Reviewer acknowledgement Published on:

  28. Current clinical practice guidelines recommend the use of prophylactic doses of low molecular weight heparins for cancer patients requiring hospitalization for acute medical illness. However, a recently publis...

    Authors: Patricia Moretto, Junghyun Park, Marc Rodger, Grégoire Le Gal and Marc Carrier
    Citation: Thrombosis Journal 2015 13:10
    Content type: Original clinical investigation Published on:

  29. Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the prin...

    Authors: Herm Jan M Brinkman
    Citation: Thrombosis Journal 2015 13:9
    Content type: Review Published on:

  31. Behçet’s disease (BD) is a rare vasculitis in sub-Saharan Africa. Vascular thrombosis, especially venous, is common in this condition and also constitutes a basic diagnostic criterion. Its affection of the sup...

    Authors: Simon Antoine Sarr, Pape Diadie Fall, Mouhamadou Chérif Mboup, Khadidiatou Dia, Malick Bodian and Modou Jobe
    Citation: Thrombosis Journal 2015 13:7
    Content type: Case report Published on:

  32. Edoxaban is an oral, direct, factor Xa inhibitor approved in Japan for thromboembolic prophylaxis after lower-limb orthopedic surgery (LLOS), but contraindicated in patients with severe renal impairment (SRI; ...

    Authors: Takeshi Fuji, Satoru Fujita, Yohko Kawai, Yasuyuki Abe, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe and Shintaro Tachibana
    Citation: Thrombosis Journal 2015 13:6
    Content type: Original clinical investigation Published on:

  35. Ideal conditions for platelet reactivity testing are critical for optimal selection of a P2Y12 inhibitor. Data are inconsistent regarding the impact of high-fat meals on test assessment.

    Authors: Paul P Dobesh, Jamela F Urban, Scott W Shurmur and Julie H Oestreich
    Citation: Thrombosis Journal 2015 13:3
    Content type: Original clinical investigation Published on:

  36. The global EINSTEIN DVT and PE studies compared rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K antagonist therapy and demonstrated non-inferiority for effica...

    Authors: Norikazu Yamada, Atsushi Hirayama, Hideaki Maeda, Satoru Sakagami, Hiroo Shikata, Martin H Prins, Anthonie WA Lensing, Masaharu Kato, Junichi Onuma, Yuki Miyamoto, Kazuma Iekushi and Mariko Kajikawa
    Citation: Thrombosis Journal 2015 13:2
    Content type: Original clinical investigation Published on:

    The Erratum to this article has been published in Thrombosis Journal 2016 14:11

  38. Homocysteine is an amino acid that is toxic to vascular endothelial cells, and plasma elevations have been associated with venous thromboembolism. Severe hyperhomocysteinemia (>100 μmol/L) may result from muta...

    Authors: Zuhier Awan, Sumayah Aljenedil, David S Rosenblatt, Jean Cusson, Brian M Gilfix and Jacques Genest
    Citation: Thrombosis Journal 2014 12:30
    Content type: Case report Published on:

  39. Mild therapeutic hypothermia is considered standard care in the treatment of patients resuscitated from cardiac arrest. With increasingly more frequent concomitant use of platelet-inhibiting drugs, clinicians ...

    Authors: Sven Van Poucke, Kris Stevens, Abraham Emanuel Marcus and Marcus Lancé
    Citation: Thrombosis Journal 2014 12:31
    Content type: Review Published on:

  41. In clinical trials new oral anticoagulants (NOAC) have proved to be as effective as warfarin for thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate the efficacy and safety of thes...

    Authors: Ashkan Labaf, Martin Carlwe and Peter J Svensson
    Citation: Thrombosis Journal 2014 12:29
    Content type: Original clinical investigation Published on:

  42. Venous thromboembolism (VTE) requires urgent diagnosis and treatment to avoid related complications. Clinical presentations of VTE are nonspecific and require definitive confirmation by imaging techniques. A c...

    Authors: Tarek Owaidah, Nahlah AlGhasham, Saad AlGhamdi, Dania AlKhafaji, Bandar ALAmro, Mohamed Zeitouni, Fawaz Skaff, Hazzaa AlZahrani, Adher AlSayed, Naser ElKum, Mahmoud Moawad, Ahmed Nasmi, Mohannad Hawari and Khalid Maghrabi
    Citation: Thrombosis Journal 2014 12:28
    Content type: Original clinical investigation Published on:

  43. Statins may reduce the risk of first and recurrent venous thromboembolism (VTE). No data are available on their potential benefit in patients treated with the oral anticoagulant rivaroxaban.

    Authors: Philip S Wells, Martin Gebel, Martin H Prins, Bruce L Davidson and Anthonie WA Lensing
    Citation: Thrombosis Journal 2014 12:26
    Content type: Original clinical investigation Published on:

  44. Patients with renal impairment receiving classical anticoagulation for venous thromboembolism (VTE) are at increased risk of bleeding and possibly pulmonary embolism. We examined the efficacy and safety of ora...

    Authors: Rupert M Bauersachs, Anthonie WA Lensing, Martin H Prins, Dagmar Kubitza, Ákos F Pap, Hervé Decousus, Jan Beyer-Westendorf and Paolo Prandoni
    Citation: Thrombosis Journal 2014 12:25
    Content type: Original basic research Published on:

  45. Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment...

    Authors: Jonathan Douxfils, Anne Tamigniau, Bernard Chatelain, Catherine Goffinet, Jean-Michel Dogné and François Mullier
    Citation: Thrombosis Journal 2014 12:24
    Content type: Review Published on:

  47. Increasing age and renal impairment are risk factors for venous thrombosis but also for anticoagulant-induced bleeding. In large-scale phase III trials, non-VKA oral anticoagulants (NOACs) were at least as eff...

    Authors: Vincent Geldhof, Christophe Vandenbriele, Peter Verhamme and Thomas Vanassche
    Citation: Thrombosis Journal 2014 12:21
    Content type: Review Published on:

  48. Warfarin is known for its interaction with many drugs, resulting in undesired treatment outcomes such as bleeding. The study aimed to assess the prevalence of drug-drug interactions and determinants of bleedin...

    Authors: Gebrehiwot Teklay, Nuredin Shiferaw, Befikadu Legesse and Mebratu Legesse Bekele
    Citation: Thrombosis Journal 2014 12:20
    Content type: Original clinical investigation Published on:

  49. Enoxaparin displays fibrinolytic activity through stimulation of endothelial release of tissue plasminogen activator. Moreover, enoxaparin increases the release of tissue factor pathway inhibitor, which inhibi...

    Authors: Gesa Wiegand, Vanya Icheva, Martin Schöning and Michael Hofbeck
    Citation: Thrombosis Journal 2014 12:19
    Content type: Case report Published on:

  50. Erythropoietin (Epo) has been shown to improve myocardial function in models of experimental myocardial infarction, but has also been associated with a rise in thromboembolic events. Thus, the aim of this stud...

    Authors: Gabriele Demetz, Magdalena Laux, Armin Scherhag, Tiny Hoekstra, Marit M Suttorp, Friedo Dekker, Mark Roest, Mira Marcus-Kalish, Moshe Mittelman and Ilka Ott
    Citation: Thrombosis Journal 2014 12:18
    Content type: Original clinical investigation Published on:
Submit manuscript

Official journal of

  • APSTH logo

  • Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.6
    5-year Journal Impact Factor: 3.1
    Source Normalized Impact per Paper (SNIP): 0.653
    SCImago Journal Rank (SJR): 0.572

    Speed 2023
    Submission to first editorial decision (median days): 11
    Submission to acceptance (median days): 107

    Usage 2023
    Downloads: 708,004
    Altmetric mentions: 943

Thrombosis Journal

ISSN: 1477-9560

Contact us